<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Celltrion（068270.KS）已与一家全球制药公司签署了合同制造协议，供应药物原料。Celltrion 将在 2027 年至 2029 年期间供应药物原料，合同价值约为 2949 亿韩元，可能扩展至 3754 亿韩元。</p>
<p>在今年早些时候，Celltrion 与礼来公司签署了 CMO 合同，随着新协议的增加，该公司的累计 CMO 订单积压在今年第一季度超过了 1 万亿韩元。Celltrion 表示正在审查国内外的额外制造设施，以确保足够的基础设施并支持不断增长的全球 CDMO 需求。</p>
<p>Celltrion 的股票交易价格为 206,500 韩元，上涨 3.25%。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

CYCN

标普生物技术 ETF - SPDR

LCTX

<p>Celltrion 与一家全球制药公司签署了合同制造协议，计划在 2027 年至 2029 年期间供应药物原料，合同价值约为 2949 亿韩元，可能扩展至 3754 亿韩元。该协议增加了 Celltrion 的合同制造订单积压，已超过 1 万亿韩元。公司还在探索额外的生产设施，以满足日益增长的全球需求。Celltrion 的股价上涨了 3.25%，达到 206,500 韩元</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Celltrion (068270.KS) has signed a contract manufacturing agreement with a global pharmaceutical company for the supply of drug substance. Celltrion will supply drug substance for three years from 2027 through 2029. The contract value is approximately 294.9 billion Korean won and may expand to 375.4 billion won.</p>
<div class="lb-trans"><p>Celltrion（068270.KS）已与一家全球制药公司签署了合同制造协议，供应药物原料。Celltrion 将在 2027 年至 2029 年期间供应药物原料，合同价值约为 2949 亿韩元，可能扩展至 3754 亿韩元。</p>
</div><p>Earlier in the current year, Celltrion signed a CMO contract with Eli Lilly, and with the addition of new agreement, the company's cumulative CMO order backlog surpassed 1 trillion won within the first quarter of the year. Celltrion noted that it is reviewing additional manufacturing facilities both domestically and overseas to ensure sufficient infrastructure and support growing global CDMO demand.</p>
<div class="lb-trans"><p>在今年早些时候，Celltrion 与礼来公司签署了 CMO 合同，随着新协议的增加，该公司的累计 CMO 订单积压在今年第一季度超过了 1 万亿韩元。Celltrion 表示正在审查国内外的额外制造设施，以确保足够的基础设施并支持不断增长的全球 CDMO 需求。</p>
</div><p>Celltrion shares are trading at 2,06,500 won, up 3.25%.</p>
<div class="lb-trans"><p>Celltrion 的股票交易价格为 206,500 韩元，上涨 3.25%。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Celltrion 与一家全球制药公司达成合同制造协议